-- Clinical development focus on high-potential XmAb ® T cell engagers and selective dual checkpoint inhibitor, vudalimab -- -- Vudalimab (PD-1 x CTLA-4) monotherapy generally well tolerated with encouraging clinical benefit for patients with high-risk mCRPC who have advanced beyond standard of
PASADENA, Calif. --(BUSINESS WIRE)--Feb. 20, 2024-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will report financial results for the fourth
PASADENA, Calif. --(BUSINESS WIRE)--Jan. 3, 2024-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat , Ph.D., president and chief executive
PASADENA, Calif. --(BUSINESS WIRE)--Jan. 2, 2024-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Dane Leone , CFA, has joined Xencor as senior vice
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 21, 2023-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today announced that company management will present at the
-- Royalty Transaction Generates $215 Million Upfront -- -- Management to Host Conference Call at 4:30 p.m. ET Today -- PASADENA, Calif. --(BUSINESS WIRE)--Nov. 7, 2023-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 7, 2023-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the sale of portions of financial interests from Alexion
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 3, 2023-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today presented data from multiple preclinical-stage XmAb ® programs at the
PASADENA, Calif. --(BUSINESS WIRE)--Oct. 31, 2023-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release third quarter 2023 financial results after
PASADENA, Calif. --(BUSINESS WIRE)--Oct. 26, 2023-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, announced that John J. Kuch , senior vice president and chief financial
